The Q1 earnings beat is marginal and overshadowed by rising operating losses. The stock will trade on pipeline catalysts: watch for the FDA Type A meeting outcome in Q2 and the Phase 3 APOLLO topline data in Q4 2026, which are the primary value drivers. The $730M cash runway into 2029 removes near-term financing risk.
IRON drugs
IRON drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $67.59entry
- T+1 · 7mo ago +1.57%α +0.18% · $68.65
- T+5 · 6mo ago +2.43%α +0.44% · $69.23
- T+20 · 6mo ago +0.61%α −4.35% · $68.00
- T+60 · 4mo ago +17.19%α +14.45% · $79.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63.5M from $34.1M a year ago on higher R&D and SG&A costs. The key catalyst is the completed enrollment of the Phase 3 APOLLO trial for bitopertin in EPP, with topline data expected in Q4 2026, which could support an FDA resubmission by mid-2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$1.65 vs consensus -$1.73 (4.6% beat)
- Net loss widened to $63.5M from $34.1M YoY, driven by higher R&D ($45.9M vs $27.8M) and SG&A ($23.6M vs $12.2M)
- Cash, cash equivalents, and marketable securities of $730.2M, providing runway into 2029
- Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (183 patients); topline data expected Q4 2026
- Type A meeting with FDA scheduled for Q2 2026 to discuss bitopertin CRL response; potential FDA decision by mid-2027
- Updated Phase 2 data for DISC-0974 in MF anemia to be presented at ASCO in June 2026
- Phase 2 data for DISC-3405 in PV and Phase 1b data in SCD expected Q4 2026
Financial Impact
Net loss of $63.5M in Q1 2026 vs $34.1M in Q1 2025; cash burn of ~$61M in the quarter
Risk Factors
- Bitopertin Phase 3 APOLLO trial failure or disappointing topline data in Q4 2026
- FDA Type A meeting could result in additional clinical requirements, delaying bitopertin approval
- Rising operating expenses without near-term revenue could pressure valuation if pipeline milestones slip
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287684 |
Track record
43 reports on IRON
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers